| (Values in U.S. Thousands) | Sep, 2016 | Jun, 2016 | Mar, 2016 | Dec, 2015 | Sep, 2015 |
| Sales | 32,090 | 38,860 | 36,220 | 43,370 | 47,320 |
| Sales Growth | -17.42% | +7.29% | -16.49% | -8.35% | -4.98% |
| Net Income | -19,990 | -19,960 | -6,380 | 76,100 | -29,690 |
| Net Income Growth | -0.15% | -212.85% | -108.38% | +356.32% | -70.63% |
Flamel Technologies (FLML)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Flamel Technologies S.A. is principally engaged in the development of advanced polymer technologies for unique medicinal applications. To meet important medical needs and develop commercially valuable products, they are building on their primary technology platforms: the Medusa system for the controlled peritoneal delivery of proteins and peptides, and the Micropump system for the controlled delivery of certain oral drugs. (press release)